Researchers at the Stanford University School of Medicine say they are puzzled by findings from their new study indicating that an antidepressant, which previously showed promise in treating a behavioral disorder known as compulsive buying, did not result in a sustained benefit for the patients who took it.
A new study reported that zolpidem, a drug normally used to treat insomnia, temporarily improved brain function in a patient suffering from akinetic mutism, a condition in which the person is alert but cannot speak or move.
Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the American College of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans.
Takeda and FDA notified healthcare professionals of recent safety data concerning pioglitazone-containing products. The results of an analysis of the manufacturer’s clinical trial database of pioglitazone showed more reports of fractures in female patients taking pioglitazone than those taking a comparator (either placebo or active).
CV Therapeutics, Inc. (NASDAQ: CVTX) announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ranolazine. The study did not meet the primary efficacy endpoint.
Postmenopausal women without symptoms of cardiovascular problems who have minor or major abnormalities on an electrocardiogram are at increased risk for future cardiovascular events and death, according to a study in the March 7 issue of JAMA.
Getting enough calcium and vitamin D while reducing calorie intake can increase the beneficial effects of weight loss on cholesterol levels adding to the number of mechanisms by which calcium can benefit weight loss on blood fats.
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that it presented additional results of its completed Phase 2 follow-on study of Flurizan? in patients with mild Alzheimer’s disease at the annual meeting of the American Association for Geriatric Psychiatry (AAGP), held March 1-4, 2007 in New Orleans.
Results from two ongoing Phase III studies of ISENTRESS? (raltegravir), an investigational oral integrase inhibitor, demonstrated significantly greater antiretroviral activity of ISENTRESS when used in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV-infected patients who had failed antiretroviral therapies (ARTs), and who had HIV virus resistant to at least one drug in each of the three available classes of oral ARTs.
A new candidate vaccine against hepatitis E, developed collaboratively by GlaxoSmithKline (GSK) and the Walter Reed Army Institute of Research (WRAIR), was found to be 95.5% effective in a Phase Two trial, according to a study to be published in the New England Journal of Medicine.